2.Y. Wu, J. Zhao, J. Hu,etc.388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study[J].ESMO Asia Congress 2022.3. 牛娜.非小细胞肺癌 ＭＥＴ基因...
[1]Gow CH, Hsieh MS, Chen YL, Liu YN, Wu SG, Shih JY. Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: A single-center real-world study. Front Oncol. 2023;13:1113696....
JTO Clinical and Research Reports杂志2024年2月发表了一篇题为Cabozantinib response in a patient with NSCLC harboring both MET exon 14 skipping mutation and secondary RET fusion: a case report的文章,讲述了一个因MET突变产生...
MET的主要变异形式包括外显子14跳跃突变(Exon 14 skipping mutation)、基因扩增(Gene amplification)以及蛋白过表达(Protein overexpression)。 MET外显子14跳跃突变 MET外显子14跳跃突变是一种罕见突变,非小细胞肺癌发生率少于5%,对于老年、肺腺癌患者有略高的发生率,可通过逆转录PCR法或二代测序进行检测。 这种突变...
EXON 14 SKIPPING MUTATION 首页/癌基因/MET/ EXON 14 SKIPPING MUTATION MET基因编码的蛋白为肝细胞生长因子受体HGFR,具有酪氨酸激酶活性,与多种癌基因产物和调节蛋白相关,参与细胞信息传导、细胞骨架重排的调控,是细胞增殖、分化和运动的重要因素。目前认为,c-met与多种癌的发生和转移密切相关,研究表明,许多肿瘤病人...
[8] Socinski MA, Pennell NA, Davies KD. MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations. JCO Precis Oncol. 2021 Apr 13;5:PO.20.00516. [9] Liu SY, Gou LY, Li AN et al. The unique characteristics of...
[5] Fujino T, Suda K, Mitsudomi T. Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer (Auckl). 2021 May 20;12:35-50. [6]《非小细胞肺癌分子病理检测临床实践指南》2021版 ...
在我们认真阅读基因检测报告时,相信会经常看到错义突变、移码突变、截短突变等耳熟能详的基因变异类型。然而,当初次发现变异类型为MET 14号外显子跳跃突变(MET exon 14 skipping,下称MET 14跳突)的时候,你很可能会感到很新颖,基因还有跳跃突变呢?然后一连串的问题,陷入茫然,跳跃突变是啥啊?可以用靶向药吗... ...
本期「In China For Global - MET 新例量」分享 1 例 MET ex14 跳突晚期 NSCLC 患者,采用赛沃替尼 600 mg QD 一线治疗,获得了缩小的疾病稳定(SD),至最后一次随访时无进展生存期(PFS)超 17 个月。该病例由锦州医科大学附属第一医院刘晓梅教授、王玉玺医师提供,并邀请大连医科大学附属第一医院张春霞教授点评...
[3]. MET 14外显子跳跃突变NSCLC靶向治疗专家共识. [4]. NCCN NSCLC临床指南非小细胞肺癌.2024.v1 [5]. 2023 CSCO非小细胞肺癌诊疗指南. [6].Leighl N,et al. Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study. 2023 WCLC OA21.04 ...